Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)

Author(s):
McClung, M.; Langdahl, B.; Papapoulos, S.; Saag, K.; Adami, S.; Bone, H.; Villiers, T. de; Kiel, D.; Kung, A.; Kumar, P.; Lim, S.K.; Ling, X.; Lippuner, K.; Mautalen, C.; Nakamura, T.; Reginster, J.Y.; Reid, I.; Portales, J.R.; Roux, C.; Walliser, J.; Watts, N.; Zanchetta, J.R.; Zerbini, C.; Rybak-Feiglin, A.; Cohn, D.; DaSilva, C.; Massaad, R.; Santora, A.; Scott, B.; Verbruggen, N.; Leung, A.; Lombardi, A.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-02-28
Language
English
Is part of
Journal of Bone and Mineral Research (2014), Vol. 29, p. S51-S51
hdl
1887/101285